Cannabinoid receptor gene polymorphisms and cognitive performance in patients with schizophrenia and controls

Rodrigo Ferretjans; Renan P. de Souza; Bruna Panizzutti; Pâmela Ferrari; Lucas Mantovani; Salvina M. de Campos-Carli; Rafael R. Santos; Fernanda C. Guimarães; Antonio L. Teixeira; Clarissa S. Gama; João Vinícius Salgado

doi:10.1590/1516-4446-2020-1650

Cannabinoid receptor gene polymorphisms and cognitive performance in patients with schizophrenia and controls

Rodrigo Ferretjans, Renan P. de Souza, Bruna Panizzutti, Pâmela Ferrari, Lucas Mantovani, Salvina M. de Campos-Carli, Rafael R. Santos, Fernanda C. Guimarães, Antonio L. Teixeira, Clarissa S. Gama, João Vinícius Salgado

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Objective: To test the hypothesis that genetic variations of cannabinoid receptors contribute to the pathophysiology of cognitive deficits in schizophrenia. Methods: In this genetic association case-control study, cannabinoid receptor polymorphisms CNR1 rs12720071 and CNR2 rs2229579 were tested for association with neurocognitive performance in 69 patients with schizophrenia and 45 healthy controls. Neurocognition was assessed by the Brief Assessment of Cognition in Schizophrenia (BACS). Results: We found a consistent association between CNR1 rs12720071 polymorphism and the cognitive performance of patients in several cognitive domains. Patients with C/C polymorphism presented significantly worse performance in motor speed, verbal fluency, attention/processing speed and reasoning/problem solving. Conclusion: Although limited, our data support the hypothesis that CNR1 variations may be associated with the pathogenesis of cognitive deficits of schizophrenia.

Original language	English (US)
Pages (from-to)	26-34
Number of pages	9
Journal	Brazilian Journal of Psychiatry
Volume	44
Issue number	1
DOIs	https://doi.org/10.1590/1516-4446-2020-1650
State	Published - 2022
Externally published	Yes

Keywords

CNR1
CNR2
Cannabinoids
Cognitive dysfunction
Endocannabinoids
Schizophrenia

ASJC Scopus subject areas

Psychiatry and Mental health

Access to Document

10.1590/1516-4446-2020-1650

Cite this

Ferretjans, R., de Souza, R. P., Panizzutti, B., Ferrari, P., Mantovani, L., de Campos-Carli, S. M., Santos, R. R., Guimarães, F. C., Teixeira, A. L., Gama, C. S., & Salgado, J. V. (2022). Cannabinoid receptor gene polymorphisms and cognitive performance in patients with schizophrenia and controls. Brazilian Journal of Psychiatry, 44(1), 26-34. https://doi.org/10.1590/1516-4446-2020-1650

Ferretjans, R, de Souza, RP, Panizzutti, B, Ferrari, P, Mantovani, L, de Campos-Carli, SM, Santos, RR, Guimarães, FC, Teixeira, AL, Gama, CS & Salgado, JV 2022, 'Cannabinoid receptor gene polymorphisms and cognitive performance in patients with schizophrenia and controls', Brazilian Journal of Psychiatry, vol. 44, no. 1, pp. 26-34. https://doi.org/10.1590/1516-4446-2020-1650

@article{5db8299288c94b9283e3b5ff50766314,

title = "Cannabinoid receptor gene polymorphisms and cognitive performance in patients with schizophrenia and controls",

abstract = "Objective: To test the hypothesis that genetic variations of cannabinoid receptors contribute to the pathophysiology of cognitive deficits in schizophrenia. Methods: In this genetic association case-control study, cannabinoid receptor polymorphisms CNR1 rs12720071 and CNR2 rs2229579 were tested for association with neurocognitive performance in 69 patients with schizophrenia and 45 healthy controls. Neurocognition was assessed by the Brief Assessment of Cognition in Schizophrenia (BACS). Results: We found a consistent association between CNR1 rs12720071 polymorphism and the cognitive performance of patients in several cognitive domains. Patients with C/C polymorphism presented significantly worse performance in motor speed, verbal fluency, attention/processing speed and reasoning/problem solving. Conclusion: Although limited, our data support the hypothesis that CNR1 variations may be associated with the pathogenesis of cognitive deficits of schizophrenia.",

keywords = "CNR1, CNR2, Cannabinoids, Cognitive dysfunction, Endocannabinoids, Schizophrenia",

author = "Rodrigo Ferretjans and {de Souza}, {Renan P.} and Bruna Panizzutti and P{\^a}mela Ferrari and Lucas Mantovani and {de Campos-Carli}, {Salvina M.} and Santos, {Rafael R.} and Guimar{\~a}es, {Fernanda C.} and Teixeira, {Antonio L.} and Gama, {Clarissa S.} and Salgado, {Jo{\~a}o Vin{\'i}cius}",

year = "2022",

doi = "10.1590/1516-4446-2020-1650",

language = "English (US)",

volume = "44",

pages = "26--34",

journal = "Brazilian Journal of Psychiatry",

issn = "1516-4446",

publisher = "Associacao Brasileira de Psiquiatria",

number = "1",

}

TY - JOUR

T1 - Cannabinoid receptor gene polymorphisms and cognitive performance in patients with schizophrenia and controls

AU - Ferretjans, Rodrigo

AU - de Souza, Renan P.

AU - Panizzutti, Bruna

AU - Ferrari, Pâmela

AU - Mantovani, Lucas

AU - de Campos-Carli, Salvina M.

AU - Santos, Rafael R.

AU - Guimarães, Fernanda C.

AU - Teixeira, Antonio L.

AU - Gama, Clarissa S.

AU - Salgado, João Vinícius

PY - 2022

Y1 - 2022

N2 - Objective: To test the hypothesis that genetic variations of cannabinoid receptors contribute to the pathophysiology of cognitive deficits in schizophrenia. Methods: In this genetic association case-control study, cannabinoid receptor polymorphisms CNR1 rs12720071 and CNR2 rs2229579 were tested for association with neurocognitive performance in 69 patients with schizophrenia and 45 healthy controls. Neurocognition was assessed by the Brief Assessment of Cognition in Schizophrenia (BACS). Results: We found a consistent association between CNR1 rs12720071 polymorphism and the cognitive performance of patients in several cognitive domains. Patients with C/C polymorphism presented significantly worse performance in motor speed, verbal fluency, attention/processing speed and reasoning/problem solving. Conclusion: Although limited, our data support the hypothesis that CNR1 variations may be associated with the pathogenesis of cognitive deficits of schizophrenia.

AB - Objective: To test the hypothesis that genetic variations of cannabinoid receptors contribute to the pathophysiology of cognitive deficits in schizophrenia. Methods: In this genetic association case-control study, cannabinoid receptor polymorphisms CNR1 rs12720071 and CNR2 rs2229579 were tested for association with neurocognitive performance in 69 patients with schizophrenia and 45 healthy controls. Neurocognition was assessed by the Brief Assessment of Cognition in Schizophrenia (BACS). Results: We found a consistent association between CNR1 rs12720071 polymorphism and the cognitive performance of patients in several cognitive domains. Patients with C/C polymorphism presented significantly worse performance in motor speed, verbal fluency, attention/processing speed and reasoning/problem solving. Conclusion: Although limited, our data support the hypothesis that CNR1 variations may be associated with the pathogenesis of cognitive deficits of schizophrenia.

KW - CNR1

KW - CNR2

KW - Cannabinoids

KW - Cognitive dysfunction

KW - Endocannabinoids

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=85124632922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85124632922&partnerID=8YFLogxK

U2 - 10.1590/1516-4446-2020-1650

DO - 10.1590/1516-4446-2020-1650

M3 - Article

C2 - 34190825

AN - SCOPUS:85124632922

SN - 1516-4446

VL - 44

SP - 26

EP - 34

JO - Brazilian Journal of Psychiatry

JF - Brazilian Journal of Psychiatry

IS - 1

ER -

Cannabinoid receptor gene polymorphisms and cognitive performance in patients with schizophrenia and controls

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this